STAT News

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.

By STAT News

1 min read
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights